Drugs In-Vivo Medicine Pharma Companies 
pharmaphorum
FEBRUARY 13, 2022
German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.
Camargo
NOVEMBER 11, 2020
When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.
Drug Discovery World
AUGUST 22, 2023
Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. What are complex generics?
Drug Discovery World
SEPTEMBER 28, 2022
Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery. . Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace.
Drug Discovery World
NOVEMBER 16, 2022
DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .
Drug Discovery World
APRIL 3, 2023
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.
Expert insights. Personalized for you.
98 
Let's personalize your content